Dodge & Cox’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $589M | Buy |
1,955,393
+26,140
| +1% | +$7.88M | 0.31% | 83 |
|
|
2026
Q1 | $638M | Sell |
1,929,253
-35,162
| -2% | -$12M | 0.35% | 78 |
|
|
2025
Q4 | $781M | Sell |
1,964,415
-356,815
| -15% | -$158M | 0.42% | 69 |
|
|
2025
Q3 | $1.06B | Sell |
2,321,230
-875,866
| -27% | -$357M | 0.57% | 58 |
|
|
2025
Q2 | $1.04B | Sell |
3,197,096
-154,666
| -5% | -$42.8M | 0.59% | 52 |
|
|
2025
Q1 | $905M | Sell |
3,351,762
-188,500
| -5% | -$48.4M | 0.52% | 61 |
|
|
2024
Q4 | $833M | Sell |
3,540,262
-82,273
| -2% | -$21.6M | 0.48% | 68 |
|
|
2024
Q3 | $996M | Sell |
3,622,535
-157,650
| -4% | -$41M | 0.56% | 60 |
|
|
2024
Q2 | $919M | Sell |
3,780,185
-31,295
| -0.8% | -$4.94M | 0.55% | 62 |
|
|
2024
Q1 | $570M | Buy |
3,811,480
+137,170
| +4% | +$22.9M | 0.33% | 78 |
|
|
2023
Q4 | $703M | Sell |
3,674,310
-72,845
| -2% | -$12.4M | 0.45% | 73 |
|
|
2023
Q3 | $664M | Sell |
3,747,155
-42,370
| -1% | -$8.08M | 0.45% | 69 |
|
|
2023
Q2 | $720M | Sell |
3,789,525
-105,010
| -3% | -$20.8M | 0.48% | 69 |
|
|
2023
Q1 | $780M | Sell |
3,894,535
-696,247
| -15% | -$146M | 0.53% | 62 |
|
|
2022
Q4 | $1.09B | Sell |
4,590,782
-298,515
| -6% | -$63.7M | 0.75% | 52 |
|
|
2022
Q3 | $979M | Sell |
4,889,297
-369,659
| -7% | -$70.5M | 0.74% | 52 |
|
|
2022
Q2 | $767M | Sell |
5,258,956
-216,712
| -4% | -$30.7M | 0.53% | 60 |
|
|
2022
Q1 | $894M | Buy |
5,475,668
+44,600
| +0.8% | +$6.79M | 0.54% | 61 |
|
|
2021
Q4 | $921M | Buy |
5,431,068
+58,968
| +1% | +$11M | 0.57% | 57 |
|
|
2021
Q3 | $1.01B | Sell |
5,372,100
-41,901
| -0.8% | -$7.86M | 0.66% | 55 |
|
|
2021
Q2 | $918M | Buy |
5,414,001
+1,092,374
| +25% | +$160M | 0.6% | 57 |
|
|
2021
Q1 | $610M | Sell |
4,321,627
-318,286
| -7% | -$47.9M | 0.44% | 60 |
|
|
2020
Q4 | $603M | Sell |
4,639,913
-37,700
| -0.8% | -$5.03M | 0.48% | 59 |
|
|
2020
Q3 | $681M | Sell |
4,677,613
-26,058
| -0.6% | -$3.7M | 0.62% | 53 |
|
|
2020
Q2 | $697M | Sell |
4,703,671
-389,675
| -8% | -$52.5M | 0.64% | 54 |
|
|
2020
Q1 | $554M | Sell |
5,093,346
-157,975
| -3% | -$18.2M | 0.6% | 52 |
|
|
2019
Q4 | $605M | Sell |
5,251,321
-60,480
| -1% | -$6.03M | 0.46% | 58 |
|
|
2019
Q3 | $427M | Buy |
5,311,801
+70,300
| +1% | +$5.56M | 0.35% | 67 |
|
|
2019
Q2 | $380M | Buy |
5,241,501
+243,500
| +5% | +$18.7M | 0.31% | 70 |
|
|
2019
Q1 | $467M | Buy |
4,998,001
+307,750
| +7% | +$25.7M | 0.38% | 66 |
|
|
2018
Q4 | $342M | Buy |
4,690,251
+34,600
| +0.7% | +$2.66M | 0.31% | 71 |
|
|
2018
Q3 | $407M | Buy |
4,655,651
+950
| +0% | +$95.6K | 0.31% | 71 |
|
|
2018
Q2 | $458M | Sell |
4,654,701
-38,140
| -0.8% | -$3.78M | 0.37% | 68 |
|
|
2018
Q1 | $559M | Sell |
4,692,841
-3,538,754
| -43% | -$456M | 0.45% | 63 |
|
|
2017
Q4 | $1.05B | Sell |
8,231,595
-909,900
| -10% | -$114M | 0.81% | 48 |
|
|
2017
Q3 | $1.07B | Sell |
9,141,495
-44,325
| -0.5% | -$3.78M | 0.86% | 46 |
|
|
2017
Q2 | $733M | Sell |
9,185,820
-213,425
| -2% | -$13.6M | 0.62% | 53 |
|
|
2017
Q1 | $482M | Buy |
9,399,245
+194,295
| +2% | +$8.98M | 0.41% | 66 |
|
|
2016
Q4 | $345M | Buy |
9,204,950
+3,928,882
| +74% | +$164M | 0.31% | 70 |
|
|
2016
Q3 | $358M | Buy |
5,276,068
+2,759,399
| +110% | +$195M | 0.34% | 67 |
|
|
2016
Q2 | $140M | Buy |
+2,516,669
| New | +$159M | 0.14% | 71 |
|
Other funds holding ALNY
Dodge & Cox's ALNY Position: Q2 2026 in Review
Dodge & Cox increased its Alnylam Pharmaceuticals (ALNY) stake by 1.4% in Q2 2026, buying an estimated $7.88M and bringing the position to 1,955,393 shares worth $589M. The position accounts for 0.31% of the portfolio, ranked #83.
Dodge & Cox first reported a position in ALNY in Q2 2016 and has held it in 41 quarters since. The position peaked at $1.09B in Q4 2022. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Dodge & Cox held 1,955,393 shares of Alnylam Pharmaceuticals worth $589M as of Q2 2026.
- Dodge & Cox bought 26,140 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.88M.
- Alnylam Pharmaceuticals made up 0.31% of Dodge & Cox's portfolio in Q2 2026, its #83 holding.
- Dodge & Cox first reported a position in Alnylam Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
- Dodge & Cox's Alnylam Pharmaceuticals position peaked at $1.09B in Q4 2022.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Dodge & Cox's 13F filing for Q2 2026, filed 13 Aug 2026.